Mankind Pharma
Mankind Pharma, a prominent player in the Indian pharmaceutical industry, is headquartered in New Delhi, India. Founded in 1991, the company has established itself as a leader in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and consumer healthcare items. With a strong focus on quality and innovation, Mankind Pharma has achieved significant milestones, including rapid expansion across major operational regions in India and beyond. The company is renowned for its unique formulations and commitment to affordable healthcare, positioning itself as a trusted name among healthcare professionals and consumers alike. Notable achievements include a robust market presence and recognition for its contributions to the pharmaceutical sector, making Mankind Pharma a key player in enhancing health outcomes across the region.
DitchCarbon Score
How does Mankind Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mankind Pharma's score of 11 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mankind Pharma's reported carbon emissions
In 2024, Mankind Pharma reported total carbon emissions of approximately 19,562,000 kg CO2e, comprising 5,831,000 kg CO2e from Scope 1 and 13,731,000 kg CO2e from Scope 2. This marks a significant reduction from 2023, where emissions totalled about 43,596,000 kg CO2e, with Scope 1 at 14,519,000 kg CO2e and Scope 2 at 29,077,000 kg CO2e. In 2022, the company recorded emissions of approximately 43,294,000 kg CO2e, with Scope 1 emissions at 15,753,000 kg CO2e and Scope 2 at 28,074,000 kg CO2e. This indicates a downward trend in emissions over the years, showcasing Mankind Pharma's commitment to reducing its carbon footprint. Despite the positive trajectory in emissions reduction, Mankind Pharma has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on improving its emission intensity, with figures indicating a reduction in emissions per rupee of turnover and per unit of pharmaceutical products produced. Overall, Mankind Pharma's efforts reflect a growing commitment to sustainability and climate responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,753,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 28,074,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mankind Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
